Patents by Inventor Julian Davies

Julian Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150438
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Application
    Filed: March 31, 2023
    Publication date: May 9, 2024
    Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
  • Publication number: 20240101670
    Abstract: The present disclosure relates to antibodies that bind human LAIR1 (“anti-human LAIR1 antibodies” or “anti-human LAIR1 antibodies”), compositions comprising such anti-human LAIR1 antibodies, and methods of using such anti-human LAIR1 antibodies.
    Type: Application
    Filed: September 15, 2023
    Publication date: March 28, 2024
    Inventors: Julian DAVIES, Scott Charles POTTER, Andrew Charles VENDEL, Wei WANG, Reid Martin Renny FELDMAN, Shireen Syrah KHAN, Monica MACAL, Maria Elena AYALA RAMIREZ
  • Publication number: 20230167115
    Abstract: The present disclosure relates to the use of antiviral agents that are cladoniamides and derivatives thereof such as the compound Formula I, for example, for the treatment of viral infections such as those caused by coronaviruses and/or flaviviruses. The present disclosure also includes antiviral agents and methods for their preparation.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 1, 2023
    Inventors: François Jean, Raymond Andersen, David Williams, Julian Davies, Rory Long, Tirosh Shapira, Weeda Morsal Mamozai
  • Publication number: 20220356229
    Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Application
    Filed: March 4, 2021
    Publication date: November 10, 2022
    Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
  • Patent number: 11447541
    Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: September 20, 2022
    Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
  • Patent number: 11370828
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: June 28, 2022
    Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
  • Patent number: 11267882
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • Publication number: 20210388066
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 16, 2021
    Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.
    Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
  • Publication number: 20210292393
    Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.
    Type: Application
    Filed: December 9, 2020
    Publication date: September 23, 2021
    Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Hunman Servi
    Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
  • Patent number: 10913793
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Publication number: 20200048340
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Patent number: 10501536
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 10, 2019
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
  • Publication number: 20190266911
    Abstract: Provided herein are various conditioned response toilet training systems and methods. The various embodiments described herein include components for detecting elimination events reliably and quickly; notifying caregivers of these elimination events; conditioning children such that a specific cue or set of cues becomes associated with the act of elimination; training one or more caregivers to learn the behavioral antecedents and overall elimination patterns of the child; predicting elimination events so that caregivers may be prospectively notified of a likely elimination; and training children to communicate their elimination needs to caregivers.
    Type: Application
    Filed: January 29, 2019
    Publication date: August 29, 2019
    Inventors: Adam Michael DOUGHERTY, Julian Davies
  • Publication number: 20190233508
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Application
    Filed: March 24, 2017
    Publication date: August 1, 2019
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • Publication number: 20180118821
    Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 3, 2018
    Inventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel
  • Patent number: 9394362
    Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 19, 2016
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
  • Publication number: 20160125759
    Abstract: Provided herein are various conditioned response toilet training systems and methods. The various embodiments described herein include components for detecting elimination events reliably and quickly; notifying caregivers of these elimination events; conditioning children such that a specific cue or set of cues becomes associated with the act of elimination; training one or more caregivers to learn the behavioral antecedents and overall elimination patterns of the child; predicting elimination events so that caregivers may be prospectively notified of a likely elimination; and training children to communicate their elimination needs to caregivers.
    Type: Application
    Filed: October 29, 2015
    Publication date: May 5, 2016
    Inventors: Adam Michael DOUGHERTY, Julian DAVIES
  • Patent number: 9260531
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: February 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Gregory Beuerlein, Julian Davies, Irene Jennifer Denning, Ling Liu, Jirong Lu, Peter Edward Vaillancourt
  • Patent number: 9201074
    Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof, that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 1, 2015
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Ling Liu, Jirong Lu
  • Publication number: 20150266954
    Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 24, 2015
    Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder